CROVALIMAB
( DrugBank: Crovalimab / KEGG DRUG: Crovalimab )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 48 | Primary antiphospholipid syndrome | 1 |
| 62 | Paroxysmal nocturnal hemoglobinuria | 33 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 109 | Atypical hemolytic uremic syndrome | 16 |
48. Primary antiphospholipid syndrome
Clinical trials : 96 / Drugs : 112 - (DrugBank : 22) / Drug target genes : 20 - Drug target pathways : 138
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
62. Paroxysmal nocturnal hemoglobinuria
Clinical trials : 380 / Drugs : 240 - (DrugBank : 38) / Drug target genes : 28 - Drug target pathways : 122
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
109. Atypical hemolytic uremic syndrome
Clinical trials : 130 / Drugs : 44 - (DrugBank : 5) / Drug target genes : 2 - Drug target pathways : 11
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|